Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions

Relapsed/Refractory Leukemia

Interventions

DRUG

Plitidepsin plus Cytarabine

Plitidepsin 0.54 mg /m2 (initial dose)daily x 5 one hour infusion every 3 weeks plus Cytarabine 1 g/m2 daily for 5 days.

Trial Locations (1)

The Cancer Institute of New Jersey, New Brunswick